[Intravenous and oral treatment with amantadine sulfate in Parkinson disease].
The rapid efficacy of amantadine on akinesia and rigidity in Parkinson's disease is generally known. The duration of this therapeutic result is however controversial. Some authors have reported a loss of efficacy after only a few weeks of therapy. The success of a short-term parenteral and subsequently oral long-term treatment with amantadine sulphate in 8 Parkinsonian patients was tested by means of clinical and neuropsychological examinations and by monitoring the serum concentration over the course of half a year. A ten-day intravenous treatment with amantadine sulphate (200 mg daily) led to a significant improvement in the clinical and psychological test results. This attained improvement could be maintained for 6 months with oral therapy consisting of 600 mg amantadine sulphate. There were strong interindividual variations in serum concentration.
Brenner
M
M
Universitäts-Nervenklinik, Neurologie, Homburg/Saar.
Haass
A
A
Jacobi
P
P
Schimrigk
K
K
D000284:Administration, Oral; D000547:Amantadine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000097:blood / Q000188:drug therapy*
D000547:Amantadine
Intravenöse und orale Behandlung mit Amantadinsulfat bei der Parkinsonkrankheit.